Optimizing Frontline Treatment Approaches in EGFRm Metastatic NSCLC - Episode 6
Panelists discuss how explaining survival benefits to patients must be tailored to individual goals and expectations, with many patients having specific life milestones they hope to reach.
Communicating Survival Benefits and Treatment Trade-Offs
Main Discussion Topics:
Key Points for Physicians:
Notable Insights:
Data from a Chinese survey showed that over 70% of patients, family members, and doctors would prefer osimertinib monotherapy over combination therapy despite a 9-month delay in recurrence with the latter.
Clinical Significance:
Effective shared decision-making requires understanding individual patient goals and preferences rather than making assumptions based on demographic factors or physician biases.